Literature DB >> 28508340

Comparative effects of sertraline, haloperidol or olanzapine treatments on ketamine-induced changes in mouse behaviours.

O J Onaolapo1, T B Paul2, A Y Onaolapo3.   

Abstract

Effects of sertraline, haloperidol or olanzapine administration on ketamine-induced behaviours in mice were examined. The aim was to ascertain the degree of reversal of such behaviours by sertraline, and compare its effectiveness to haloperidol and olanzapine. Ten-week old mice (N = 120) were equally divided into main groups; 1 (open-field, radial-arm maze and elevated plus maze {EPM} tests), and 2 (social interaction test). Mice in each main group were assigned into six groups of ten (n = 10) each. Group 1 received intraperitoneal (i.p) injection of vehicle, while groups 2-6 received i.p ketamine at 15 mg/kg daily for 10 days. From day 11 to 24, mice in group 1 (vehicle) were given distilled water (i.p at 2 ml/kg and oral at 10 ml/kg), group 2 (ketamine control) received daily i.p ketamine and oral distilled water; while animals in groups 3-6 received daily i.p. ketamine and oral haloperidol (4 mg/kg), olanzapine (2 mg/kg), or one of two doses of sertraline (SERT) (2.5 or 5 mg/kg), respectively. Treatments were administered daily, and behaviours assessed on days 11 and 24. Results showed that repeated ketamine administration caused hyperlocomotion, increased self-grooming, memory loss and social withdrawal. Administration of sertraline (both doses), haloperidol, and olanzapine reversed ketamine-induced behavioural changes. However, in the EPM, sertraline and olanzapine were anxiolytic, while haloperidol was anxiogenic. Sertraline's effect on behaviours tested was comparable to olanzapine and better than haloperidol. In conclusion, this study shows that sertraline's ability to counteract ketamine-induced behavioural changes in mice is comparable to known antipsychotics.

Entities:  

Keywords:  Dopamine antagonist; NMDA receptor antagonist; Neurobehaviour; Schizophrenia; Selective serotonin re-uptake inhibitors

Mesh:

Substances:

Year:  2017        PMID: 28508340     DOI: 10.1007/s11011-017-0031-3

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  80 in total

1.  Aspartame and the hippocampus: Revealing a bi-directional, dose/time-dependent behavioural and morphological shift in mice.

Authors:  Adejoke Y Onaolapo; Olakunle J Onaolapo; Polycarp U Nwoha
Journal:  Neurobiol Learn Mem       Date:  2016-12-31       Impact factor: 2.877

2.  Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats.

Authors:  Yuji Kitaichi; Takeshi Inoue; Shin Nakagawa; Shuken Boku; Aya Kakuta; Takeshi Izumi; Tsukasa Koyama
Journal:  Eur J Pharmacol       Date:  2010-09-09       Impact factor: 4.432

3.  Effects of 5-hydroxytryptamine 2C receptor agonist MK212 and 2A receptor antagonist MDL100907 on maternal behavior in postpartum female rats.

Authors:  Weihai Chen; Qi Zhang; Wenxin Su; Haorong Zhang; Yu Yang; Jing Qiao; Nan Sui; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2013-12-07       Impact factor: 3.533

4.  alpha(7) Nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment.

Authors:  Morten S Thomsen; Ditte Z Christensen; Henrik H Hansen; John P Redrobe; Jens D Mikkelsen
Journal:  Neuropharmacology       Date:  2009-02-21       Impact factor: 5.250

Review 5.  Role of the cholinergic system in the pathology and treatment of schizophrenia.

Authors:  Elizabeth Scarr; Brian Dean
Journal:  Expert Rev Neurother       Date:  2009-01       Impact factor: 4.618

6.  Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models.

Authors:  E Engin; D Treit; C T Dickson
Journal:  Neuroscience       Date:  2009-03-24       Impact factor: 3.590

7.  Possible evidence of angiotensin II and endogenous opioid modulation of novelty-induced rearing in the rat.

Authors:  A A Ajayi; O E Ukponmwan
Journal:  Afr J Med Med Sci       Date:  1994-09

8.  Strain- and model-dependent effects of chlordiazepoxide, L-838,417 and zolpidem on anxiety-like behaviours in laboratory mice.

Authors:  L S Mathiasen; N R Mirza; R J Rodgers
Journal:  Pharmacol Biochem Behav       Date:  2008-01-31       Impact factor: 3.533

Review 9.  The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue.

Authors:  Ralf Brisch; Arthur Saniotis; Rainer Wolf; Hendrik Bielau; Hans-Gert Bernstein; Johann Steiner; Bernhard Bogerts; Katharina Braun; Anna Katharina Braun; Zbigniew Jankowski; Jaliya Kumaratilake; Jaliya Kumaritlake; Maciej Henneberg; Tomasz Gos
Journal:  Front Psychiatry       Date:  2014-05-19       Impact factor: 4.157

Review 10.  Augmentation with antidepressants in schizophrenia treatment: benefit or risk.

Authors:  Ye-Meng Mao; Ming-Dao Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-16       Impact factor: 2.570

View more
  3 in total

1.  Ketamine-induced behavioural and brain oxidative changes in mice: an assessment of possible beneficial effects of zinc as mono- or adjunct therapy.

Authors:  Olakunle James Onaolapo; Olayemi Quyyom Ademakinwa; Temitayo Opeyemi Olalekan; Adejoke Yetunde Onaolapo
Journal:  Psychopharmacology (Berl)       Date:  2017-06-14       Impact factor: 4.530

2.  Sertraline Delivered in Phosphatidylserine Liposomes Is Effective in an Experimental Model of Visceral Leishmaniasis.

Authors:  Maiara Maria Romanelli; Thais Alves da Costa-Silva; Edezio Cunha-Junior; Daiane Dias Ferreira; Juliana M Guerra; Andres Jimenez Galisteo; Erika Gracielle Pinto; Leandro R S Barbosa; Eduardo Caio Torres-Santos; Andre Gustavo Tempone
Journal:  Front Cell Infect Microbiol       Date:  2019-10-29       Impact factor: 5.293

3.  Mirogabalin Decreases Pain-like Behaviours and Improves Opioid and Ketamine Antinociception in a Mouse Model of Neuropathic Pain.

Authors:  Renata Zajączkowska; Ewelina Rojewska; Agata Ciechanowska; Katarzyna Pawlik; Katarzyna Ciapała; Magdalena Kocot-Kępska; Wioletta Makuch; Jerzy Wordliczek; Joanna Mika
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.